Shigella vaccine - LimmaTech Biologics

Drug Profile

Shigella vaccine - LimmaTech Biologics

Alternative Names: Flexyn2a; GVXN-SD133; Shigella dysenteriae bioconjugate vaccine - GlycoVaxyn; Shigella flexneri 2a vaccine - GlycoVaxyn

Latest Information Update: 05 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlycoVaxyn
  • Developer GlycoVaxyn; Johns Hopkins Bloomberg School of Public Health; LimmaTech Biologics
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Shigella infections
  • Discontinued Intestinal infections

Most Recent Events

  • 01 Jul 2017 LimmaTech Biologics completes a phase II trial in Shigella infections (Prevention, In adults) in USA (IM) (NCT02646371)
  • 10 Aug 2016 Discontinued - Phase-I for Intestinal infections caused by Shigella (Prevention, In adults) in Switzerland (IM)
  • 10 Aug 2016 Shigella vaccine - LimmaTech Biologics receives Fast Track designation for Shigella infections (Prevention, In adults) in USA before August 2016 (IM,Injection) (LimmaTech Biologics communication, August 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top